Pirh2 Antibody

Product Discontinued

Pirh2 Antibody Summary

• Immunogen: The immunogen recognized by this antibody maps to a region between residues 1 and 50 of human ring finger and CHY zinc finger domain containing 1 using the numbering given in entry NP_05625.1 (GeneID 25898).
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: RCHY1
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation 1-4 ug/mg of lysate
  • Western Blot 1:1000-1:10000
• Control:

  Pirh2 Overexpression Lysate

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: Tris-Citrate/Phosphate (pH 7.0 - 8.0)
• Preservative: 0.09% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for Pirh2 Antibody

• Androgen receptor N-terminal-interacting protein
• androgen-receptor N-terminal-interacting protein
• ARNIPRING finger protein 199
• CHIMPRNF199DKFZp586C1620
• CH-rich interacting match with PLAG1
• CH-rich-interacting match with PLAG1
• E3 ubiquitin-protein ligase Pirh2
• EC 6.3.2.-
• hARNIP
• hPirh2
• PIRH2
• PRO1996
• ring finger and CHY zinc finger domain containing 1
• RING finger and CHY zinc finger domain-containing protein 1
• Zinc finger protein 363p53-induced RING-H2 protein
• ZNF363

Background

This gene encodes a protein involved in nonsense-mediated mRNA decay (NMD) as part of the mRNA surveillance complex. The protein has kinase activity and is thought to function in NMD by phosphorylating the regulator of nonsense transcripts 1 protein. Alternative spliced transcript variants have been described, but their full-length natures have not been determined.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Pirh2 Antibody (NB100-2318)(9)

Publications using NB100-2318

• Sion-Vardy N, Freedman J, Lazarov I et al. p27kip1 Expression in non-small cell lung cancer is not an independent prognostic factor. Anticancer Res 2010-09-01 [PMID: 20944156]
• Corcoran CA, Montalbano J, Sun H et al. Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains. J Biol Chem 2009-08-01 [PMID: 19483087]
• Duan S, Yao Z, Zhu Y et al. The Pirh2-keratin 8/18 interaction modulates the cellular distribution of mitochondria and UV-induced apoptosis. Cell Death Differ 2009-06-01 [PMID: 19282868]
• Sheng Y, Laister RC, Lemak A et al. Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol 2008-12-01 [PMID: 19043414]
• Duan S, Yao Z, Hou D et al. Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53. EMBO J 2007-07-01 [PMID: 17568776]
• Koivusalo R, Mialon A, Pitkanen H et al. Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists. Cancer Res 2006-12-01 [PMID: 17178878]
• Duan W, Gao L, Wu X et al. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. Exp Cell Res 2006-10-01 [PMID: 16934800]
• Yoneda-Kato N, Tomoda K, Umehara M et al. Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3. EMBO J 2005-05-01 [PMID: 15861129]
• Duan W, Gao L, Druhan LJ et al. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst 2004-11-01 [PMID: 15547185]

Bioinformatics

• Gene Symbol: RCHY1
• Entrez:
  • 25898(Human)